Dr Reddy’s Share Price: Citi trims target after setback in Semaglutide generic – Markets
Dr Reddy’s Laboratories’ share price will be in focus after Citi reiterated its Sell rating and trimmed its outlook on the stock following regulatory setbacks linked to its generic semaglutide ambitions. The brokerage slashed the target price to Rs 1,070, implying a 13 per cent downside from current market price. The brokerage flagged concerns after…
